PS
ACAD icon

Principal Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Principal Securities’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
+10,006
New +$220K ﹤0.01% 1400
2025
Q4 		– Sell
-1,043
Closed -$22.3K – 1362
2025
Q3 		$22.3K Buy
1,043
+454
+77% +$10.7K ﹤0.01% 2358
2025
Q2 		$12.7K Buy
589
+576
+4,431% +$10.7K ﹤0.01% 2521
2025
Q1 		$239 Hold
13
– – ﹤0.01% 3439
2024
Q4 		$239 Buy
+13
New +$210 ﹤0.01% 3434

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Principal Securities's ACAD Position: Q2 2026 in Review

Principal Securities opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 10,006 shares worth $253K. The stake represents ﹤0.01% of the portfolio and ranks #1400 among its holdings. This is a return to the name: Principal Securities previously reported a position in ACAD as recently as Q3 2025.

Principal Securities first reported a position in ACAD in Q4 2024 and has held it in 5 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Principal Securities held 10,006 shares of Acadia Pharmaceuticals worth $253K as of Q2 2026.
  • Acadia Pharmaceuticals was a new Principal Securities position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Principal Securities's portfolio in Q2 2026, its #1400 holding.
  • Principal Securities first reported a position in Acadia Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Principal Securities's 13F filing for Q2 2026, filed 4 Aug 2026.